Patient safety and blood transfusion: new solutions.
Dzik WH, Corwin H, Goodnough LT, et al.
Transfus Med Rev 2003;17(3):169-180.
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP
J Pain Symptom Manage 2003;25(6):512-518.
Managing uncontrolled hemorrhage in trauma and surgery: a novel and promising approach.
Can J Anaesth 2002;49(10):S4-S6.
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales.
Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE
J Pain Symptom Manage 2002;24(6):547-561.
Review by Ford PA
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response... Read More
Continuous infusion of coagulation factor products.
Stachnik JM, Gabay MP
Ann Pharmacother 2002;36(5):882-891.
Experience with use of recombinant activated factor VII.
Divanon F, Hecquard C, Borel-Derlon A
J Clin Pharm Ther 2002;27(2):133-138.
Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
Kooistra MP, Kersting S, Gosriwatana I, et al.
Eur J Clin Invest 2002;32:36-41:36-41.
Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
The authors evaluated a low dose iron substitution scheme for the effectiveness in patients with peritoneal dialysis: 50 mg iron sucrose every other week is... Read More
Epinephrine versus epinephrine plus fibrin glue injection in peptic ulcer bleeding: a prospective randomized trial.
A useful study (notwithstanding power) and review of current practices. – F. Regan and M. Contreras.
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
Gerotziafas GT, Zervas C, Gavrielidis G, et al.
Am J Hematol 2002;69(3):219-222.
Review by M. Aldouri
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
O’Connell N, McMahon C, Smith J, et al.
Br J Haematol 2002;116(3):632-635.
Review by Aldouri M
Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH, Chang CC, Chiang SS
Clin Nephrol 2002;57(2):136-141.
Review by Gasche C
Iron administration and clinical outcomes in hemodialysis patients.
Feldman HI, Santanna J, Guo WS, et al.
J Am Soc Nephrol 2002;13(3):734-744.
Review by Gasche C
Surgery-associated acquired hemophilia A.
Theodossiades G, Tsevrenis N, Nomikou E, Dadiotis L, Kontopoulou-Griva I
Ann Hematol 2001;80(11):691-693.